117279-73-9

117279-73-9 structure

Name: Israpafant
Chemical Name: Israpafant
CAS Number: 117279-73-9
Molecular Formula: C₂₈H₂₉ClN₄S
Molecular Weight: 489.07
Catalog: Research Areas Inflammation/Immunology
Create Date: 2016-09-02 19:25:08
Modify Date: 2025-08-27 12:05:41
Israpafant (Y-24180) is a potent, selective and long-acting platelet activation factor (PAF) receptor antagonist with IC50s of 0.84 nM and 3.84 nM against PAF-induced human and rabbit platelet aggregation, respectively. Israpafant stimulates both extracellular Ca2+ influx and intracellular Ca2+ release in prostate cancer cells. Israpafant suppresses the allergic cutaneous reactions including eosinophilia, cytokine production, edema and erythema in mice[1][2].

Name	Israpafant

Description	Israpafant (Y-24180) is a potent, selective and long-acting platelet activation factor (PAF) receptor antagonist with IC50s of 0.84 nM and 3.84 nM against PAF-induced human and rabbit platelet aggregation, respectively. Israpafant stimulates both extracellular Ca2+ influx and intracellular Ca2+ release in prostate cancer cells. Israpafant suppresses the allergic cutaneous reactions including eosinophilia, cytokine production, edema and erythema in mice[1][2].
Related Catalog	Research Areas >> Inflammation/Immunology
Target	IC50: 0.84 nM (PAF-induced human platelet aggregation), 3.84 nM (PAF-induced rabbit platelet aggregation)[1]
References	[1]. Takehara S, et al. Pharmacological actions of Y-24180, a new specific antagonist of platelet activating factor (PAF): II. Interactions with PAF and benzodiazepine receptors. Prostaglandins. 1990 Dec;40(6):571-83. [2]. Jan C R, Chao Y Y. Novel effect of Y-24180, a presumed specific platelet activation factor receptor antagonist, on Ca2+ levels and growth of human prostate cancer cells. Cellular signalling, 2004, 16(8): 959-965.